YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...
MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...
StudyFinds on MSN1d
Scientists create ‘living’ gels that heal themselves like human tissueDiscover the power of hydrogel: researchers at Penn State mimic tissue behaviors using special hydrogels for potential ...
A research team from the Eye & ENT Hospital of Fudan University, China, has developed a novel biocompatible nanoadhesive for ...
Exosomes, naturally occurring extracellular vesicles, have garnered increasing interest in the field of cosmetics and skincare due to their regenerative pr | Drug Discovery And Development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback